Patterns of use and cost for inappropriate radioactive iodine treatment for thyroid cancer in the United States: Use and misuse
Menée à partir des données 1998-2011 de registres américains des cancers, cette étude identifie les formes d'utilisation abusive ou non appropriée de traitements à base d'iode radioactif dans le cancer de la thyroïde, puis évalue les coûts associés
Based on current guidelines, adjuvant radioactive iodine (RAI) therapy is not recommended for localized papillary thyroid tumors measuring 1 cm or less, medullary thyroid cancer (MTC), and anaplastic thyroid cancer (ATC).1- 3 Nevertheless, previous studies have reported the use of RAI in the treatment of these cancers. The aim of the current study was to analyze patterns of inappropriate RAI use in the United States to identify potential misuses leading to increased costs for the health care system and unnecessary patient exposure to the risk and potential complications of RAI therapy.